Effective chemotherapy for advanced CNS embryonal tumors in adults

Evanthia Galanis, Jan Craig Buckner, P. J. Schomberg, J. E. Hammock, C. Raffel, B. W. Scheithauer

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose: Embryonal tumors of the CNS include, among others, medulloblastoma, cerebral neuroblastoma, pineoblastoma, and primitive neuroectodermal tumors (PNETs). Almost all data on the treatment of embryonal CNS tumors are derived from the pediatric population, since these tumors are uncommon in adulthood. The purpose of this study was to examine the rate and duration of response to chemotherapy of advanced embryonal CNS tumors in adults. Patients and Methods: We retrospectively studied all adult (> 18 years of age) patients with advanced embryonal tumors of the CNS who received chemotherapy at our institution between 1976 and 1994. Seventeen consecutive patients were treated with regimens that contained either nitrosourea or cisplatin or both sequentially, with no patients having received the combination of nitrosourea and cisplatin concurrently. Results: In patients who received cisplatin-based chemotherapy, responses were observed in 84.5% (26% complete response [CR] rate), 10.5% remained stable, and 5% progressed. The median time to progression was 18 months for patients who had a CR, 6 months for those with partial response (PR), and 10 months for stable patients. Among patients who received nitrosourea-based chemotherapy, PR was observed in 27%, 36.5% remained stable, and 36.5% progress. The median time to progression was 6 months for patients who had a PR and 6.5 months for stable patients. Conclusion: In adults with advanced embryonal CNS tumors, conventional-dose intravenous cisplatin-based chemotherapy regimens are able to produce responses in the majority of the patients (84.5%), even as second- or third-line regimens. Nitrosourea-based regimens less frequently produce responses (27%).

Original languageEnglish (US)
Pages (from-to)2939-2944
Number of pages6
JournalJournal of Clinical Oncology
Volume15
Issue number8
StatePublished - Aug 1997

Fingerprint

Drug Therapy
Neoplasms
Cisplatin
Pinealoma
Primitive Neuroectodermal Tumors
Medulloblastoma
Neuroblastoma
Pediatrics
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Galanis, E., Buckner, J. C., Schomberg, P. J., Hammock, J. E., Raffel, C., & Scheithauer, B. W. (1997). Effective chemotherapy for advanced CNS embryonal tumors in adults. Journal of Clinical Oncology, 15(8), 2939-2944.

Effective chemotherapy for advanced CNS embryonal tumors in adults. / Galanis, Evanthia; Buckner, Jan Craig; Schomberg, P. J.; Hammock, J. E.; Raffel, C.; Scheithauer, B. W.

In: Journal of Clinical Oncology, Vol. 15, No. 8, 08.1997, p. 2939-2944.

Research output: Contribution to journalArticle

Galanis, E, Buckner, JC, Schomberg, PJ, Hammock, JE, Raffel, C & Scheithauer, BW 1997, 'Effective chemotherapy for advanced CNS embryonal tumors in adults', Journal of Clinical Oncology, vol. 15, no. 8, pp. 2939-2944.
Galanis E, Buckner JC, Schomberg PJ, Hammock JE, Raffel C, Scheithauer BW. Effective chemotherapy for advanced CNS embryonal tumors in adults. Journal of Clinical Oncology. 1997 Aug;15(8):2939-2944.
Galanis, Evanthia ; Buckner, Jan Craig ; Schomberg, P. J. ; Hammock, J. E. ; Raffel, C. ; Scheithauer, B. W. / Effective chemotherapy for advanced CNS embryonal tumors in adults. In: Journal of Clinical Oncology. 1997 ; Vol. 15, No. 8. pp. 2939-2944.
@article{3eb3811f41da428097975180b9ff4c5c,
title = "Effective chemotherapy for advanced CNS embryonal tumors in adults",
abstract = "Purpose: Embryonal tumors of the CNS include, among others, medulloblastoma, cerebral neuroblastoma, pineoblastoma, and primitive neuroectodermal tumors (PNETs). Almost all data on the treatment of embryonal CNS tumors are derived from the pediatric population, since these tumors are uncommon in adulthood. The purpose of this study was to examine the rate and duration of response to chemotherapy of advanced embryonal CNS tumors in adults. Patients and Methods: We retrospectively studied all adult (> 18 years of age) patients with advanced embryonal tumors of the CNS who received chemotherapy at our institution between 1976 and 1994. Seventeen consecutive patients were treated with regimens that contained either nitrosourea or cisplatin or both sequentially, with no patients having received the combination of nitrosourea and cisplatin concurrently. Results: In patients who received cisplatin-based chemotherapy, responses were observed in 84.5{\%} (26{\%} complete response [CR] rate), 10.5{\%} remained stable, and 5{\%} progressed. The median time to progression was 18 months for patients who had a CR, 6 months for those with partial response (PR), and 10 months for stable patients. Among patients who received nitrosourea-based chemotherapy, PR was observed in 27{\%}, 36.5{\%} remained stable, and 36.5{\%} progress. The median time to progression was 6 months for patients who had a PR and 6.5 months for stable patients. Conclusion: In adults with advanced embryonal CNS tumors, conventional-dose intravenous cisplatin-based chemotherapy regimens are able to produce responses in the majority of the patients (84.5{\%}), even as second- or third-line regimens. Nitrosourea-based regimens less frequently produce responses (27{\%}).",
author = "Evanthia Galanis and Buckner, {Jan Craig} and Schomberg, {P. J.} and Hammock, {J. E.} and C. Raffel and Scheithauer, {B. W.}",
year = "1997",
month = "8",
language = "English (US)",
volume = "15",
pages = "2939--2944",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Effective chemotherapy for advanced CNS embryonal tumors in adults

AU - Galanis, Evanthia

AU - Buckner, Jan Craig

AU - Schomberg, P. J.

AU - Hammock, J. E.

AU - Raffel, C.

AU - Scheithauer, B. W.

PY - 1997/8

Y1 - 1997/8

N2 - Purpose: Embryonal tumors of the CNS include, among others, medulloblastoma, cerebral neuroblastoma, pineoblastoma, and primitive neuroectodermal tumors (PNETs). Almost all data on the treatment of embryonal CNS tumors are derived from the pediatric population, since these tumors are uncommon in adulthood. The purpose of this study was to examine the rate and duration of response to chemotherapy of advanced embryonal CNS tumors in adults. Patients and Methods: We retrospectively studied all adult (> 18 years of age) patients with advanced embryonal tumors of the CNS who received chemotherapy at our institution between 1976 and 1994. Seventeen consecutive patients were treated with regimens that contained either nitrosourea or cisplatin or both sequentially, with no patients having received the combination of nitrosourea and cisplatin concurrently. Results: In patients who received cisplatin-based chemotherapy, responses were observed in 84.5% (26% complete response [CR] rate), 10.5% remained stable, and 5% progressed. The median time to progression was 18 months for patients who had a CR, 6 months for those with partial response (PR), and 10 months for stable patients. Among patients who received nitrosourea-based chemotherapy, PR was observed in 27%, 36.5% remained stable, and 36.5% progress. The median time to progression was 6 months for patients who had a PR and 6.5 months for stable patients. Conclusion: In adults with advanced embryonal CNS tumors, conventional-dose intravenous cisplatin-based chemotherapy regimens are able to produce responses in the majority of the patients (84.5%), even as second- or third-line regimens. Nitrosourea-based regimens less frequently produce responses (27%).

AB - Purpose: Embryonal tumors of the CNS include, among others, medulloblastoma, cerebral neuroblastoma, pineoblastoma, and primitive neuroectodermal tumors (PNETs). Almost all data on the treatment of embryonal CNS tumors are derived from the pediatric population, since these tumors are uncommon in adulthood. The purpose of this study was to examine the rate and duration of response to chemotherapy of advanced embryonal CNS tumors in adults. Patients and Methods: We retrospectively studied all adult (> 18 years of age) patients with advanced embryonal tumors of the CNS who received chemotherapy at our institution between 1976 and 1994. Seventeen consecutive patients were treated with regimens that contained either nitrosourea or cisplatin or both sequentially, with no patients having received the combination of nitrosourea and cisplatin concurrently. Results: In patients who received cisplatin-based chemotherapy, responses were observed in 84.5% (26% complete response [CR] rate), 10.5% remained stable, and 5% progressed. The median time to progression was 18 months for patients who had a CR, 6 months for those with partial response (PR), and 10 months for stable patients. Among patients who received nitrosourea-based chemotherapy, PR was observed in 27%, 36.5% remained stable, and 36.5% progress. The median time to progression was 6 months for patients who had a PR and 6.5 months for stable patients. Conclusion: In adults with advanced embryonal CNS tumors, conventional-dose intravenous cisplatin-based chemotherapy regimens are able to produce responses in the majority of the patients (84.5%), even as second- or third-line regimens. Nitrosourea-based regimens less frequently produce responses (27%).

UR - http://www.scopus.com/inward/record.url?scp=0030792993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030792993&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 2939

EP - 2944

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -